---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000091"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:19:09.579218+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO

## Summary
- Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.
- Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.
- Latha Vairavan appointed CFO effective May 6, 2025.
- Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.
- PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13.

## SEC filing metadata
- accession: 0001787306-25-000091
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/0001787306-25-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/arqt-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000091
- JSON: https://secwatch.observer/filing/0001787306-25-000091.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.